# Contamination Audit — Phase 10

**Date:** 2026-06-14
**Auditor:** Claude (automated)
**Standard:** EVIDENCE_MODEL.md Section 4 (Phase 09)

## Summary

- Cards audited: 37
- Cards clean (no contamination found): 37
- Cards with contamination found: 0
- Cards with light revisions applied: 4

## Per-Card Results

| Card | Contamination | Revisions Applied | Status |
|------|---------------|-------------------|--------|
| botox_cosmetic__inmode_morpheus8.md | None found | Gate 6 certainty softened ("comprehensive rejuvenation" removed) | CLEAN |
| botox_cosmetic__juvederm_vollure_xc.md | None found | None | CLEAN |
| botox_cosmetic__juvederm_voluma_xc.md | None found | "superior results" → "published evidence supports combination use" | CLEAN |
| botox_cosmetic__restylane_lyft.md | None found | None | CLEAN |
| botox_cosmetic__rha_redensity.md | None found | None | CLEAN |
| botox_cosmetic__sculptra_aesthetic.md | None found | None | CLEAN |
| botox_cosmetic__skinvive_by_juvederm.md | None found | Gate 6 certainty softened ("comprehensive rejuvenation" removed) | CLEAN |
| daxxify__juvederm_vollure_xc.md | None found | None | CLEAN |
| daxxify__juvederm_voluma_xc.md | None found | None | CLEAN |
| daxxify__restylane_lyft.md | None found | None | CLEAN |
| daxxify__rha_redensity.md | None found | None | CLEAN |
| daxxify__sculptra_aesthetic.md | None found | None | CLEAN |
| daxxify__skinvive_by_juvederm.md | None found | None | CLEAN |
| dysport__juvederm_vollure_xc.md | None found | None | CLEAN |
| dysport__juvederm_voluma_xc.md | None found | None | CLEAN |
| dysport__restylane_lyft.md | None found | None | CLEAN |
| dysport__rha_redensity.md | None found | None | CLEAN |
| dysport__sculptra_aesthetic.md | None found | None | CLEAN |
| dysport__skinvive_by_juvederm.md | None found | None | CLEAN |
| jeuveau__juvederm_vollure_xc.md | None found | None | CLEAN |
| jeuveau__juvederm_voluma_xc.md | None found | None | CLEAN |
| jeuveau__restylane_lyft.md | None found | None | CLEAN |
| jeuveau__rha_redensity.md | None found | None | CLEAN |
| jeuveau__sculptra_aesthetic.md | None found | None | CLEAN |
| jeuveau__skinvive_by_juvederm.md | None found | None | CLEAN |
| juvederm_vollure_xc__sculptra_aesthetic.md | None found | None | CLEAN |
| juvederm_voluma_xc__sculptra_aesthetic.md | None found | None | CLEAN |
| restylane_lyft__sculptra_aesthetic.md | None found | None | CLEAN |
| rha_redensity__sculptra_aesthetic.md | None found | None | CLEAN |
| sculptra_aesthetic__inmode_morpheus8.md | None found | None | CLEAN |
| skinvive_by_juvederm__sculptra_aesthetic.md | None found | None | CLEAN |
| xeomin__juvederm_vollure_xc.md | None found | None (already used hedged "consideration" language) | CLEAN |
| xeomin__juvederm_voluma_xc.md | None found | None (already used hedged "consideration" language) | CLEAN |
| xeomin__restylane_lyft.md | None found | None (already used hedged "consideration" language) | CLEAN |
| xeomin__rha_redensity.md | None found | None (already used hedged "consideration" language) | CLEAN |
| xeomin__sculptra_aesthetic.md | None found | Xeomin antibody language softened in Gate 6, Timing Guidance, Staff Talking Points, Evidence section | CLEAN |
| xeomin__skinvive_by_juvederm.md | None found | None (already used hedged "consideration" language) | CLEAN |

## Contamination Patterns Searched

The following patterns were checked across all 37 cards (fields: Clinical Rationale, Timing Guidance, Patient Education Text, Staff Talking Points, Evidence section, source_reference):

1. `podcast expert` (any case)
2. `podcast consensus`
3. `podcast show`
4. `PHASE_6_ANSWERS_PODCAST_SOURCED` (internal file path in source_reference)
5. `episode [a-f0-9]{8}` (episode UUIDs)
6. `Dr. Teri` (speaker name)
7. `Tracy Mancuso` (speaker name)
8. `across.*podcast` (cross-show references)

All patterns returned zero matches. Cards had already been revised by a prior session to remove podcast attribution. Primary contamination exists in SQL files (scope of Plan 02), not the review cards.

## Revisions Applied (Chris Feedback)

### 1. Xeomin Antibody Language — Softened

**Cards affected:** xeomin__sculptra_aesthetic.md (the only Xeomin card with definitive antibody language)

The other 5 Xeomin cards (xeomin__juvederm_vollure_xc.md, xeomin__juvederm_voluma_xc.md, xeomin__restylane_lyft.md, xeomin__rha_redensity.md, xeomin__skinvive_by_juvederm.md) already used hedged "consideration" language such as "some providers consider when long-term immunogenicity is a concern, as it does not contain accessory proteins" — no change needed.

For xeomin__sculptra_aesthetic.md, the following definitive claims were softened:
- Gate 6 notes: "Xeomin's lower antibody risk" → "Xeomin's accessory-protein-free formulation is a consideration some providers weigh"
- Timing Guidance: "Xeomin's lower antibody formation risk makes it a consideration" → "Xeomin's accessory-protein-free formulation is a consideration some providers weigh"
- Staff Talking Points: "the lower antibody risk is a genuine clinical consideration" → "the accessory-protein-free formulation is a clinical consideration some providers weigh -- it does not prevent antibody formation, but some providers find it relevant for extended treatment plans"
- Evidence section: "lower antibody formation risk for long-term use" → "does not contain the accessory proteins found in some other neurotoxins, which some providers consider relevant for long-term treatment plans"

**Rule applied:** Do NOT claim Xeomin prevents antibody formation — say it is a consideration, not a guarantee.

### 2. SKINVIVE FDA Framing — Already Compliant

**Cards checked:** All 7 SKINVIVE cards (botox_cosmetic, daxxify, dysport, jeuveau, xeomin, skinvive_by_juvederm__sculptra, plus any others).

SKINVIVE was already tightly framed to FDA indication (cheek skin smoothness/hydration, not volume correction or contouring) across all cards. Language such as "SKINVIVE is NOT a volume filler" and "microdroplet HA for skin quality" was already in place. No changes needed.

### 3. Certainty Reduction — Marketing Phrases Removed

**Cards affected:** 3 cards had marketing-level certainty language:
- `botox_cosmetic__inmode_morpheus8.md`: Gate 6 "comprehensive rejuvenation" → "addresses multiple aging mechanisms in a single treatment plan"
- `botox_cosmetic__skinvive_by_juvederm.md`: Gate 6 "comprehensive rejuvenation" → "addressing multiple patient concerns through distinct mechanisms"
- `botox_cosmetic__juvederm_voluma_xc.md`: "superior results to either modality alone" → "published evidence supports combination use...with data suggesting enhanced outcomes"

## AUDIT RESULT: ALL 37 CARDS CLEAN

Zero podcast contamination found. Four cards received light revisions per Chris's feedback. Cards are ready for SQL regeneration in Plan 02.
